Association of ET-1 expression with clinicopathological variables in primary breast cancer patients
| Clinicopathological variables . | ET-1 status n positive/total (%) . | P a . |
|---|---|---|
| pT stage | ||
| pT1 | 22/68 (32.4) | 0.036b |
| pT2 | 26/52 (50.0) | |
| pT3 | 5/11 (45.5) | |
| pT4 | 16/29 (55.2) | |
| Histologic grading | ||
| I–II | 31/99 (31.3) | <0.0001 |
| III | 37/60 (61.7) | |
| Lymphovascular invasion | ||
| No | 48/122 (39.3) | NSc; 0.030 |
| Yes | 21/38 (55.3) | |
| Distant metastasis | ||
| No | 42/114 (36.8) | 0.012 |
| Yes | 27/46 (58.7) |
| Clinicopathological variables . | ET-1 status n positive/total (%) . | P a . |
|---|---|---|
| pT stage | ||
| pT1 | 22/68 (32.4) | 0.036b |
| pT2 | 26/52 (50.0) | |
| pT3 | 5/11 (45.5) | |
| pT4 | 16/29 (55.2) | |
| Histologic grading | ||
| I–II | 31/99 (31.3) | <0.0001 |
| III | 37/60 (61.7) | |
| Lymphovascular invasion | ||
| No | 48/122 (39.3) | NSc; 0.030 |
| Yes | 21/38 (55.3) | |
| Distant metastasis | ||
| No | 42/114 (36.8) | 0.012 |
| Yes | 27/46 (58.7) |